{
    "Clinical Trial ID": "NCT00950911",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W",
        "  This cohort received Zoledronic Acid 4 mg Q4W in the blinded treatment phase of the parent study 20050103 (NCT00321620) or 20050136 (NCT00321464), and received Denosumab 120 mg Q4W in this open-label extension study.",
        "INTERVENTION 2: ",
        "  Denosumab 120 mg Q4W / Denosumab 120 mg Q4W",
        "  This cohort received Denosumab 120 mg Q4W in the blinded treatment phase of the parent study 20050103 (NCT00321620) or 20050136 (NCT00321464), and received Denosumab 120 mg Q4W in this open-label extension study."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Subjects currently enrolled in study 20050103, 20050136, or 20050244",
        "  Subjects must sign the informed consent before any study specific procedures are performed",
        "Exclusion Criteria:",
        "  Developed sensitivity to mammalian cell derived drug products during the 20050103, 20050136, or 20050244 study",
        "  Currently receiving any unapproved investigational product other than denosumab",
        "  Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment",
        "  Subject (male or female) is not willing to use 2 highly effective contraception during treatment and for 7 months (women) or 10 months (men) after the end of treatment",
        "  Male subject with a pregnant partner who is not willing to use a condom during treatment and for additional 10 months after the end of treatment",
        "  Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants Survived",
        "  [Not Specified]",
        "  Time frame: 2 years",
        "Results 1: ",
        "  Arm/Group Title: Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W",
        "  Arm/Group Description: This cohort received Zoledronic Acid 4 mg Q4W in the blinded treatment phase of the parent study 20050103 (NCT00321620) or 20050136 (NCT00321464), and received Denosumab 120 mg Q4W in this open-label extension study.",
        "  Overall Number of Participants Analyzed: 17",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  13",
        "Results 2: ",
        "  Arm/Group Title: Denosumab 120 mg Q4W / Denosumab 120 mg Q4W",
        "  Arm/Group Description: This cohort received Denosumab 120 mg Q4W in the blinded treatment phase of the parent study 20050103 (NCT00321620) or 20050136 (NCT00321464), and received Denosumab 120 mg Q4W in this open-label extension study.",
        "  Overall Number of Participants Analyzed: 18",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  12"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 8/17 (47.06%)",
        "  Anaemia 0/17 (0.00%)",
        "  Atrial fibrillation 1/17 (5.88%)",
        "  Cardiac failure 1/17 (5.88%)",
        "  Diarrhoea 0/17 (0.00%)",
        "  Vomiting 0/17 (0.00%)",
        "  Death 1/17 (5.88%)",
        "  Hepatic failure 0/17 (0.00%)",
        "  Urosepsis 0/17 (0.00%)",
        "  Lumbar vertebral fracture 0/17 (0.00%)",
        "  Thoracic vertebral fracture 0/17 (0.00%)",
        "  Platelet count decreased 0/17 (0.00%)",
        "  Cachexia 1/17 (5.88%)",
        "Adverse Events 2:",
        "  Total: 10/18 (55.56%)",
        "  Anaemia 1/18 (5.56%)",
        "  Atrial fibrillation 0/18 (0.00%)",
        "  Cardiac failure 0/18 (0.00%)",
        "  Diarrhoea 1/18 (5.56%)",
        "  Vomiting 1/18 (5.56%)",
        "  Death 0/18 (0.00%)",
        "  Hepatic failure 1/18 (5.56%)",
        "  Urosepsis 1/18 (5.56%)",
        "  Lumbar vertebral fracture 1/18 (5.56%)",
        "  Thoracic vertebral fracture 1/18 (5.56%)",
        "  Platelet count decreased 1/18 (5.56%)",
        "  Cachexia 2/18 (11.11%)"
    ]
}